Patented
Know-how based
Licensee
Development partner
Commercial partner
Investment
University spin out
Integrins which have been shown to have a role in promoting angiogenesis include, αvβ3, αvβ5, and α5β1. Antagonists of RGD-binding integrins should be useful for treatment of human diseases having angiogenesis or fibrosis as a principal part of their pathology.
Researchers at Saint Louis University have developed novel integrin receptor antagonists, pharmaceutical compositions, and methods for their manufacture and use.
The potential benefits of this technology include:
Increasing the potency of anti-angiogenic activity
Increasing the possible routes for administering treatments
Minimizing the production costs for treatments
Minimizing the storage costs for treatments
The potential applications of this technology include:
treating human diseases that have angiogenesis as a principal part of their pathology
Saint Louis University is seeking a partner to further develop and commercialize this technology.